An interventional study of POINT in Substance Use Disorders and Overdose, sponsored by Indiana University. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-06.
Sponsored by Indiana University · Not applicable, Interventional, and Supportive care
Among 17 studies in Substance-Related Disorders by Indiana University — 6 open to participants now, 7 under way, none of them phase 3. Substance-Related Disorders · Indiana University.
Among the 17 studies in Substance-Related Disorders by Indiana University, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2018, is one of 12 with no phase, and was the 3rd registered.
2,241 studies on the registry are indexed under Substance-Related Disorders; 410 are open to participants now.
Browse Substance-Related Disorders studies →6 of the 17 studies in Substance-Related Disorders by Indiana University are open now, in 1 country. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 14–17
Indiana University · Sites in United States
Ages 21–50 · Healthy volunteers
Indiana University · Sites in United States
Ages 12–18
Indiana University · Sites in United States
Ages 12+
Indiana University · Sites in United States
Healthy volunteers
By country, each count listing its studies:
Of the 265 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 89 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 249 is above the median of 108 across 1,843 interventional studies indexed under Substance-Related Disorders.
Median enrollment 120 across the 13 interventional studies, 1,343 across the 4 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Indiana University is the lead sponsor of 986 studies on the registry; 198 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 118 (80%) have results posted.
3 of the studies in Substance-Related Disorders by Indiana University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05835921Indiana UniversityEnhancing Prospective Thinking in Early Recovery | 2026-11-15 |
| NCT07210268Indiana UniversityTemporal Interference Methods for Addiction Treatment | 2027-02-20 |
| NCT06084221Indiana UniversityFatal Overdose Review Teams - Research to Enhance Surveillance Systems | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Substance-Related Disorders by Indiana University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators seek to assess the effectiveness of Project POINT (Planned Outreach, Intervention, Naloxone, and Treatment). As originated in Indianapolis, Project POINT is a collaboration between Indianapolis Emergency Medical Services (EMS), the Eskenazi Emergency Department, Midtown Mental Health, and researchers at Indiana University. POINT is a quality improvement initiative that connects trained outreach workers with emergency department (ED) patients who experienced a non-fatal overdose. A member of the POINT team (a recovery coach or care coordinator with specialized training) meets patients after they have experienced an opioid overdose and, following a model of patient-centered care, offers them a range of evidence-based services including a brief assessment of high-risk behaviors, Hepatitis C and HIV testing, harm reduction counseling informed by motivational interviewing, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting
The primary goal of this project is the establishment of POINT as an effective and scalable intervention for engaging patients in MAT. This study employs a Hybrid Type 1 effectiveness implementation design to take full advantage of current POINT expansion efforts currently happening in Indiana. The goal of this study is to replicate POINT in new hospitals and test its feasibility through (a) assessment of the chosen implementation strategy and (b) the testing of research protocols and secondary data collection procedures.
STUDY DESIGN The investigators will conduct the pilot study at Indiana University Health Methodist Hospital in Indianapolis, Indiana and at Indiana University Health Ball Memorial Hospital in Muncie, Indiana.
The pilot study includes two study arms.
Arm(1): Regarding the POINT intervention, a recovery coach (someone certified by the Indiana Counselors' Association on Alcohol and Drug Abuse to deliver recovery supports who has lived experience with addiction) meets patients in the ED after they have been revived from an overdose (patients are typically alert and oriented, as the overdoes reversal drug completely stops the effect of opioids in their system, and patients will not be approached until a physician has determined they are eligible for release). As part of the POINT program, the recovery coach offers the patient a range of evidence-based services including a brief assessment of high-risk behaviors, Hepatitis C and HIV testing, harm reduction counseling informed by motivational interviewing, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting-with most patients choosing MOUD referral. Patients are offered a take-home naloxone kit (the overdose reversing drug, which is offered as part care delivered by the recovery coach) and assistance with Medicaid enrollment. Close collaboration with the local community mental health provider ensures POINT patients have their first assessment for MOUD within 1-2 business days of ED discharge. Grounded in the concept of critical time intervention, recovery coaches provide over the phone or in person support to navigate barriers to care throughout the recovery process. Also as part of the POINT program, recovery coaches offer to accompany patients to intake appointments or criminal justice and child welfare meetings as part of the standard care they deliver (no data collection for research purposes will occur as part of this service provision). The entire care transition process takes between 2 weeks and several months, and POINT leaves the door open so patients can re-engage at any point they require help overcoming recovery barriers.
Arm (2): The standard care arm will consist of basic referral to services by informing patients of available treatment options in the community.
RANDOMIZATION \& ENROLLMENT For each day of the study, researchers will randomly select during which of the shifts patients will enroll into the POINT arm and which will enroll into standard care (morning shift (8am-3:59pm), evening (4pm-11:59pm), and overnight (12am-7:59am). Any individual who is discharged from the ED for an opioid overdose or for an opioid-related health issue, including opioid withdrawal, abscess (from IV drug use) or active opioid intoxication will be eligible for the study. The research team and recovery coaches will receive an electronic alert from emergency medical services any time an overdose patient is admitted to the ED. A recovery coach will be sent to the ED on POINT shifts, and a research assistant will be sent on non-POINT shifts. Once they have confirmed that the admit is reason is either an opioid overdose or an opioid-related issue, they will read the questions on the DSM-5 for Opioid Use Disorder screening tool. Any individual who is at least 18 years of age and is discharged from the ED for an overdose an opioid related health issue AND scores at least a "1" on the opioid use disorder screening tool will be initially eligible for the study; they must also be cleared for discharge and medically stable and capable of providing consent. Depending on the arm of the study patients are being recruited to on that shift, either the recovery coach or the research assistant will inform the patient of the study and request their consent to participate.
Researchers will not fully disclose the purposes of the research to the standard care arm because (1) Methodist Hospital and Ball Memorial were planning on implementing POINT outside of the context of this study and because their ability to staff recovery coaches is limited anyway, we are not creating any disparity in patients ability to access point that would not naturally exist and (2) we are concerned that full disclosure of the purposes would unnecessarily upset standard care patients who might desire the services after learning of them.
The study site plans to implement Project POINT regardless of the research study. Therefore, all recovery coach duties are part of POINT prescribed services that would be carried out regardless of the research. The investigators are randomizing the shift during which POINT is delivered to take advantage of the fact that they are not able to fully staff all hospital shifts with a recovery coach--thus allowing us to test the intervention's effectiveness. Only those patients in the standard care arm will be asked to complete data collection activities that would not be completed outside of the research study.
After study consent, all subjects will be asked to complete a structured interview with either a recovery coach (POINT group) or a research assistant (standard care). This interview will occur in the ED, and it can take between 30-60 minutes and covers the following topics: demographics, social support; living arrangements, drug use, context of current overdose, treatment history, interest in recovery services, use of strategies to reduce risks related to drug use, HIV and Hepatitis C, physical and mental health, adverse childhood experiences, and detailed contact information. Additionally, the RA or recovery coach will collect detailed contact information on the participant to increase chances of being able to follow up with the participant. This contact information will be entered into a separate database and will not be linked to questionnaire responses.
The investigators will also collect information from the following existing secondary data sources:
As part of the POINT project, recovery coaches engage with POINT patients for two weeks (reaching out to patients every 2-3 days until the patient is successfully engaged in recovery services), but this may last longer (several months) depending on patient need and desire for continued assistance. Recovery coaches will not be collecting data for study purposes during this time; rather, any information they collect will be their employment purposes as a recovery coach. Standard care patients are not seen after the initial referral.
The investigators will also collect data from hospital records and government and public health databases on patients enrolled in the study after obtaining a release for these information from subjects. The investigators will collect methadone data from the Division of Mental Health and Addiction (DMHA), prescribing information related to controlled substances from INSPECT (prescription drug monitoring system), the hospital admission data from Indiana Network for Patient Care (INPC), overdose death information form coroner records, insurance information from Medicaid, child welfare system involvement form the Department of Child Services (DCS), and publicly available criminal justice data. A third party, Regenstrief Institute, will work with all of these systems to securely obtain and merge the data and to de-identify the data before sharing it with the research team.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
(a) Unable to answer the 3 study competency questions that indicate capability of providing consent.
(Individuals discharged from the ED during a POINT shift who do not wish to participate in the study are still eligible to receive POINT services.)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm will be offered both POINT services (in addition to standard emergency care) and enrollment in study data collection. If they choose to enroll in POINT, they may choose whether or not to enroll in data collection, as it is not required. Should they enroll in data collection, they will be consented and enrolled in the research study as a participant in the POINT study arm.
Behavioral: POINT
This arm will only be offered enrollment in study data collection, as they will receive standard emergency care. If they choose to enroll, they will be consented in the research study as the Standard Care arm.
A recovery coach meets patients in the ED after they have been revived from an overdose to offer a range of services including an assessment of high-risk behaviors, Hep C/HIV testing, harm reduction counseling, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting. Patients are offered a take-home naloxone kit and assistance with Medicaid enrollment. Close collaboration with the local community mental health provider ensures POINT patients have their first assessment for MOUD within 1-2 business days of ED discharge. Also, recovery coaches offer to accompany patients to intake appointments or criminal justice and child welfare meetings as part of the standard care they deliver.
Opioid Overdose
Total participants presenting to the emergency department (ED) for an opioid overdose.
Time frame: 1 year pre-enrollment through 1 year post-enrollment
Medication for Opioid Use Disorder (MOUD) Engagement
Total participants with buprenorphine prescriptions, naltrexone prescriptions, or dosed methadone.
Time frame: 1 year pre-enrollment through 1 year post-enrollment
Duration of Medication for Opioid Use Disorder (MOUD) Engagement
Total days of supply of buprenorphine prescriptions, naltrexone prescriptions, or methadone dosed for participants with a medication for opioid use disorder (MOUD).
Time frame: 1 year pre-enrollment through 1 year post-enrollment
Emergency Department Presentations
Total participants presented to the Emergency Department for any medical reason.
Time frame: 1 year pre-enrollment through 1 year post-enrollment
Inpatient Hospital Admissions
Total participants admitted to the hospital for any medical reason.
Time frame: 1 year pre-enrollment through 1 year post-enrollment
Time to Relapse
Relapse-free survival probability for 6 months and 12 months. Participants who did not have ED presentation were censored at 1) time of 6 month or 12 months, 2) one's last day in the study, 3) overdose death date, whichever is the earliest.
Time frame: Enrollment through 6 & 12 months post-enrollment
Medicaid Enrollment for Participants Without Insurance
Total participants without insurance coverage at enrollment that enrolled in Medicaid.
Time frame: Enrollment through 3 months, 6 months, and 12 months post-enrollment
Child Welfare Involvement
Total open child welfare cases.
Time frame: 3 years pre-enrollment through 1 year post-enrollment
Incarceration
Total days experienced incarceration.
Time frame: 3 years pre-enrollment through 1 year post-enrollment
| Milestone | POINT | Standard Care |
|---|---|---|
| Started | 159 | 90 |
| Completed | 159 | 90 |
| Not completed | 0 | 0 |
Total participants presenting to the emergency department (ED) for an opioid overdose.
| Participants | POINT | Standard Care |
|---|---|---|
| Within 12 months pre-enrollment | 18 | 9 |
| Within 6 months pre-enrollment | 10 | 6 |
| Within 3 months pre-enrollment | 5 | 4 |
| Within 1 month pre-enrollment | 0 | 3 |
| Within 1 month post-enrollment | 3 | 3 |
| Within 3 months post-enrollment | 11 | 6 |
| Within 6 months post-enrollment | 15 | 11 |
| Within 12 months post-enrollment | 26 | 15 |
Total participants with buprenorphine prescriptions, naltrexone prescriptions, or dosed methadone.
| Participants | POINT | Standard Care |
|---|---|---|
| Within 12 months pre-enrollment | 46 | 16 |
| Within 6 months pre-enrollment | 36 | 9 |
| Within 3 months pre-enrollment | 24 | 7 |
| Within 1 month pre-enrollment | 8 | 3 |
| Within 1 month post-enrollment | 36 | 14 |
| Within 3 months post-enrollment | 49 | 26 |
| Within 6 months post-enrollment | 65 | 28 |
| Within 12 months post-enrollment | 77 | 38 |
Total days of supply of buprenorphine prescriptions, naltrexone prescriptions, or methadone dosed for participants with a medication for opioid use disorder (MOUD).
| days | POINT | Standard Care |
|---|---|---|
| Within 12 months pre-enrollment | 45.0 (16.0 to 194.0) | 44.6 (27.0 to 121.0) |
| Within 6 months pre-enrollment | 41.0 (14.0 to 88.1) | 29.0 (18.0 to 97.0) |
| Within 3 months pre-enrollment | 16.0 (10.4 to 43.4) | 36.9 (14.0 to 48.9) |
| Within 1 month pre-enrollment | 14.0 (9.0 to 19.0) | 14.0 (9.0 to 14.0) |
| Within 1 month post-enrollment | 17.7 (6.7 to 24.9) | 15.9 (8.0 to 30.0) |
| Within 3 months post-enrollment | 39.0 (21.0 to 64.3) | 30.0 (8.0 to 63.3) |
| Within 6 months post-enrollment | 47.6 (21.6 to 95.0) | 47.3 (36.0 to 106.5) |
| Within 12 months post-enrollment | 84.0 (30.0 to 168.0) | 53.5 (22.0 to 207.3) |
Total participants presented to the Emergency Department for any medical reason.
| Participants | POINT | Standard Care |
|---|---|---|
| Within 12 months pre-enrollment | 99 | 52 |
| Within 6 months pre-enrollment | 77 | 43 |
| Within 3 months pre-enrollment | 55 | 30 |
| Within 1 month pre-enrollment | 29 | 18 |
| Within 1 month post-enrollment | 34 | 18 |
| Within 3 months post-enrollment | 63 | 30 |
| Within 6 months post-enrollment | 82 | 47 |
| Within 12 months post-enrollment | 102 | 56 |
Total participants admitted to the hospital for any medical reason.
| Participants | POINT | Standard Care |
|---|---|---|
| Within 12 months pre-enrollment | 44 | 23 |
| Within 6 months pre-enrollment | 29 | 17 |
| Within 3 months pre-enrollment | 21 | 9 |
| Within 1 month pre-enrollment | 10 | 4 |
| Within 1 month post-enrollment | 48 | 17 |
| Within 3 months post-enrollment | 52 | 20 |
| Within 6 months post-enrollment | 58 | 27 |
| Within 12 months post-enrollment | 71 | 36 |
Relapse-free survival probability for 6 months and 12 months. Participants who did not have ED presentation were censored at 1) time of 6 month or 12 months, 2) one's last day in the study, 3) overdose death date, whichever is the earliest.
| probability | POINT | Standard Care |
|---|---|---|
| Within 6 months post-enrollment | 0.85 (0.79 to 0.90) | 0.84 (0.75 to 0.91) |
| Within 12 months post-enrollment | 0.77 (0.70 to 0.83) | 0.74 (0.63 to 0.82) |
Total participants without insurance coverage at enrollment that enrolled in Medicaid.
| Participants | POINT | Standard Care |
|---|---|---|
| Within 3 months post-enrollment | 10 | 7 |
| Within 6 months post-enrollment | 13 | 8 |
| Within 12 months post-enrollment | 16 | 15 |
Total open child welfare cases.
| open cases | POINT | Standard Care |
|---|---|---|
| 36 months pre-enrollment | 20 | 13 |
| 24 months pre-enrollment | 19 | 12 |
| 12 months pre-enrollment | 10 | 8 |
| 6 months pre-enrollment | 5 | 4 |
| 3 months pre-enrollment | 2 | 1 |
| 1 month pre-enrollment | 0 | 0 |
| 1 month post-enrollment | 1 | 1 |
| 3 months post-enrollment | 1 | 2 |
| 6 months post-enrollment | 4 | 4 |
| 12 months post-enrollment | 9 | 4 |
Total days experienced incarceration.
| days | POINT | Standard Care |
|---|---|---|
| Within 3 years pre-enrollment | 88.0 (17.0 to 263.0) | 73.5 (11.0 to 347.0) |
| Within 2 years pre-enrollment | 39.0 (11.0 to 157.0) | 30.5 (9.0 to 183.5) |
| Within 12 months pre-enrollment | 10.0 (3.0 to 47.0) | 18.0 (5.0 to 76.0) |
| Within 6 months pre-enrollment | 6.5 (3.0 to 21.5) | 10.5 (5.0 to 71.0) |
| Within 3 months pre-enrollment | 5.5 (2.5 to 19.5) | 8.5 (4.0 to 25.0) |
| Within 1 month pre-enrollment | 6.5 (3.5 to 14.5) | 3.0 (2.0 to 13.0) |
| Within 1 month post-enrollment | 13.0 (5.0 to 24.0) | 5.5 (3.0 to 8.0) |
| Within 3 months post-enrollment | 11.0 (4.0 to 44.0) | 9.0 (4.0 to 50.0) |
| Within 6 months post-enrollment | 15.0 (4.5 to 51.0) | 10.0 (3.0 to 39.0) |
| Within 12 months post-enrollment | 19.0 (5.0 to 104.0) | 13.0 (6.0 to 47.0) |
Total participants with opioid prescriptions, excluding Medications for Opioid Use Disorder (MOUD) prescriptions.
| Participants | POINT | Standard Care |
|---|---|---|
| Within 12 months pre-enrollment | 44 | 30 |
| Within 6 months pre-enrollment | 31 | 20 |
| Within 3 months pre-enrollment | 18 | 15 |
| Within 1 month pre-enrollment | 18 | 15 |
| Within 1 month post-enrollment | 18 | 15 |
| Within 3 months post-enrollment | 8 | 6 |
| Within 6 months post-enrollment | 14 | 7 |
| Within 12 months post-enrollment | 19 | 9 |
Total participants with benzodiazepine prescriptions.
| Participants | POINT | Standard Care |
|---|---|---|
| Within 12 months pre-enrollment | 17 | 11 |
| Within 6 months pre-enrollment | 16 | 8 |
| Within 3 months pre-enrollment | 13 | 6 |
| Within 1 month pre-enrollment | 6 | 5 |
| Within 1 month post-enrollment | 10 | 5 |
| Within 3 months post-enrollment | 15 | 6 |
| Within 6 months post-enrollment | 17 | 7 |
| Within 12 months post-enrollment | 21 | 11 |
Total participants with Narcan prescriptions.
| Participants | POINT | Standard Care |
|---|---|---|
| Within 12 months pre-enrollment | 10 | 4 |
| Within 6 months pre-enrollment | 7 | 3 |
| Within 3 months pre-enrollment | 5 | 3 |
| Within 1 month pre-enrollment | 3 | 0 |
| Within 1 month post-enrollment | 7 | 3 |
| Within 3 months post-enrollment | 11 | 3 |
| Within 6 months post-enrollment | 13 | 6 |
| Within 12 months post-enrollment | 17 | 9 |
Total participants with insurance coverage at enrollment that enrolled in Medicaid.
| Participants | POINT | Standard Care |
|---|---|---|
| Within 3 months post-enrollment | 78 | 38 |
| Within 6 months post-enrollment | 83 | 41 |
| Within 12 months post-enrollment | 86 | 47 |
Collected over One year pre-enrollment through one year post-enrollment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| POINT | 25/157 (15.9%) | 102/157 (65%) | 0/157 (0%) |
| Standard Care | 16/86 (18.6%) | 56/86 (65.1%) | 0/86 (0%) |
| Event | POINT | Standard Care |
|---|---|---|
| Emergency Department PresentationGeneral disorders | 102/157 | 56/86 |
| Inpatient Hospital AdmissionGeneral disorders | 71/157 | 36/86 |
| Opioid OverdoseInjury, poisoning and procedural complications | 29/157 | 19/86 |
| Event | POINT | Standard Care |
|---|---|---|
| Violation of ConfidentialitySocial circumstances | 0/157 | 0/86 |
| Discomfort Due to InterviewSocial circumstances | 0/157 | 0/86 |
| Disclosure of Information About Harm to Self/OthersSocial circumstances | 0/157 | 0/86 |
Of the 249 participants enrolled in the study, only 243 were included in the analysis (POINT arm=157; Standard Care arm=86). A total of 6 participants, including 2 participants from the POINT arm and 4 participants from the Standard Care arm, were excluded from the analysis because they were unable to be matched to administrative records.
| Age, Continuous(years) | POINT | Standard Care | Total |
|---|---|---|---|
| Mean | 35 ± 10.1 | 37.2 ± 11.7 | 35.8 ± 10.7 |
| Sex/Gender, Customized(Participants) | POINT | Standard Care | Total |
|---|---|---|---|
| Female | 68 | 32 | 100 |
| Male | 88 | 54 | 142 |
| Other | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | POINT | Standard Care | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 |
| Not Hispanic or Latino | 153 | 84 | 237 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | POINT | Standard Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 17 | 11 | 28 |
| White | 139 | 75 | 214 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(participants) | POINT | Standard Care | Total |
|---|---|---|---|
| United States | 157 | 86 | 243 |
| Insurance Status(Participants) | POINT | Standard Care | Total |
|---|---|---|---|
| Healthy Indiana Plan (HIP) | 91 | 45 | 136 |
| Medicaid | 17 | 8 | 25 |
| Medicare | 7 | 6 | 13 |
| Private (exchange, employer-based) | 10 | 3 | 13 |
| Other | 1 | 4 | 5 |
| None | 30 | 20 | 50 |
| Unknown | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Dec 2021, 45 months.
Results were first posted in Apr 2023, 1 year 4 months after primary completion.
Of 814 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's 45 months is above that.
Counting every sponsor, half of 854 studies reached it within 34 months; a quarter within 17 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.